- Italy
- /
- Personal Products
- /
- BIT:PHN
European Growth Stocks With Strong Insider Ownership
Reviewed by Simply Wall St
Amidst a challenging economic landscape marked by fresh trade tariffs and fluctuating market sentiment, European markets have experienced some turbulence, with the pan-European STOXX Europe 600 Index recently ending about 1.4% lower. Despite these headwinds, growth companies with high insider ownership can offer unique insights into potential resilience and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In Europe
Name | Insider Ownership | Earnings Growth |
Pharma Mar (BME:PHM) | 11.8% | 40.8% |
Vow (OB:VOW) | 13.1% | 111.2% |
Elicera Therapeutics (OM:ELIC) | 27.8% | 97.2% |
Bergen Carbon Solutions (OB:BCS) | 12% | 50.8% |
CD Projekt (WSE:CDR) | 29.7% | 36.8% |
Devyser Diagnostics (OM:DVYSR) | 35.7% | 95.4% |
Elliptic Laboratories (OB:ELABS) | 22.6% | 88.2% |
Ortoma (OM:ORT B) | 27.7% | 68.6% |
Nordic Halibut (OB:NOHAL) | 29.8% | 56.3% |
Circus (XTRA:CA1) | 26% | 51.4% |
Below we spotlight a couple of our favorites from our exclusive screener.
Pharmanutra (BIT:PHN)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pharmanutra S.p.A. is a pharmaceutical and nutraceutical company that researches, designs, develops, and markets nutritional supplements and medical devices across Italy, Europe, the Middle East, South America, the Far East, and internationally with a market cap of €483.04 million.
Operations: Pharmanutra generates revenue through segments including Akern (€5.92 million), Italy (€70.24 million), and Foreign markets (€39.34 million).
Insider Ownership: 10.7%
Revenue Growth Forecast: 10.9% p.a.
Pharmanutra is experiencing robust growth, with earnings increasing by 29.4% over the past year and forecasted to grow 14.6% annually, outpacing the Italian market's average. Revenue is also expected to rise at a rate of 10.9% per year, exceeding local market trends. Recent financial results show significant improvements in sales and net income for 2024. The company announced a €1 dividend per share and presented at the Euronext Milan STAR Conference, indicating active engagement with investors.
- Get an in-depth perspective on Pharmanutra's performance by reading our analyst estimates report here.
- According our valuation report, there's an indication that Pharmanutra's share price might be on the expensive side.
Truecaller (OM:TRUE B)
Simply Wall St Growth Rating: ★★★★★★
Overview: Truecaller AB (publ) develops and publishes mobile caller ID applications for individuals and businesses across India, the Middle East, Africa, and internationally, with a market cap of approximately SEK23.46 billion.
Operations: The company's revenue segment primarily consists of Communications Software, generating SEK1.88 billion.
Insider Ownership: 29.7%
Revenue Growth Forecast: 20.1% p.a.
Truecaller is experiencing significant growth, with earnings forecasted to increase by 24.7% annually, surpassing the Swedish market average. Revenue is expected to grow over 20% per year. Recent partnerships with Telecom Egypt and Telness enhance its business offerings and security features, expanding its market presence. The company's recent iOS update introduces advanced caller ID capabilities, potentially boosting subscription revenue. Truecaller trades at a substantial discount compared to its estimated fair value, indicating potential investment appeal.
- Unlock comprehensive insights into our analysis of Truecaller stock in this growth report.
- Our expertly prepared valuation report Truecaller implies its share price may be lower than expected.
Nagarro (XTRA:NA9)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Nagarro SE, along with its subsidiaries, offers digital product engineering and technology solutions across North America, Central Europe, the rest of Europe, and internationally, with a market cap of €988.65 million.
Operations: The company generates revenue of €947.15 million from its computer services segment.
Insider Ownership: 11.8%
Revenue Growth Forecast: 10.3% p.a.
Nagarro is forecasted to grow its revenue by 10.3% annually, outpacing the German market's 6%, with earnings projected to rise at 15.69% per year. Despite high debt levels, it trades at a significant discount to its estimated fair value and analysts agree on a potential price increase of nearly 50%. Recent developments include the upcoming resignation of Supervisory Board Chair Carl Georg Dürschmidt, with succession plans set for June 2025 elections.
- Click to explore a detailed breakdown of our findings in Nagarro's earnings growth report.
- In light of our recent valuation report, it seems possible that Nagarro is trading behind its estimated value.
Summing It All Up
- Gain an insight into the universe of 236 Fast Growing European Companies With High Insider Ownership by clicking here.
- Want To Explore Some Alternatives? Uncover 13 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About BIT:PHN
Pharmanutra
A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally.
Outstanding track record with excellent balance sheet.
Similar Companies
Market Insights
Community Narratives

